Preventive Treatment of Tuberculosis with Fluoroquinolones Including Moxifloxacin in Children Exposed to Multidrug-Resistant Tuberculosis
https://doi.org/10.58838/2075-1230-2025-103-4-24-31
Abstract
The objective: to establish effectiveness and safety of preventive treatment of tuberculosis with fluoroquinolones in children exposed to multidrug-resistant tuberculosis (MDR TB) in their families.
Subjects and Methods. A cohort prospective study was conducted in Arkhangelsk Region from January 01, 2011 to December 31, 2021. Children exposed to MDR TB who received or did not receive preventive treatment were enrolled in the study.
Results. 286 children aged 0 to 18 years exposed to 939 adult MDR TB patients were included in the study. Of the 286 children, 37 were exposed to more than one adult with MDR TB, 3 children were exposed to 5 cases, 2 children were exposed to 4 cases, 8 children were exposed to 3 cases, and 24 children were exposed to 1 case. Of the 225 children who received preventive treatment with fluoroquinolones, there were no cases of tuberculosis as of March 1, 2024. Among 61 children who received no preventive treatment, there was 1 (1.64%) case of tuberculosis, which corresponded to the rate of 1639.3 per 100,000 contingent. Adverse reactions to fluoroquinolone were reported in 48/225 (21.33%) children, of which 8/225 (3.6%) were serious ones. All adverse reactions resolved.
About the Authors
T. I. Guryeva
Arkhangelsk Clinical TB Dispensary;
Northern State Medical University
Russian Federation
Russian Federation
Tatiana I. Guryeva, Head of Department for Quality Control and Statistic Reporting, Post Graduate Student of Phthisiopulmonology Department
28 Novgorodsky Ave., Arkhangelsk, 163002 Phone: +7 (8182) 66-05-62
51 Troitsky Ave., Arkhangelsk, 163069 Phone: + 7 (8182) 66-05-64
E. I. Nikishova
Northern State Medical University
Russian Federation
Russian Federation
Elena I. Nikishova, Doctor of Medical Sciences, Professor of Phthisiopulmonology Department
51 Troitsky Ave., Arkhangelsk, 163069 Phone: + 7 (8182) 66-05-64
O. A. Zolotaya
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Olga A. Zolotaya, Phthisiologist
28 Novgorodsky Ave., Arkhangelsk, 163002 Phone: +7 (8182) 66-05-62
O. M. Sveshnikova
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Oksana M. Sveshnikova, Deputy Head Doctor for Medical Activities
28 Novgorodsky Ave., Arkhangelsk, 163002 Phone: +7 (8182) 66-05-62
D. V. Perkhin
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Dmitriy V. Perkhin, Head Physician
28 Novgorodsky Ave., Arkhangelsk, 163002 Phone: +7 (8182) 66-05-62
A. O. Maryandyshev
Northern State Medical University;
Northern (Arctic) Federal University
Russian Federation
Russian Federation
Andrey O. Maryandyshev, Correspondent Member of RAS, Doctor of Medical Sciences, Professor, Head of Phthisiopulmonology Department, Leading Researcher of Research Department
51 Troitsky Ave., Arkhangelsk, 163069 Phone: + 7 (8182) 66-05-64
References
1. Klinicheskie rekomendatsii Tuberkulez u vzroslykh. [Clinical guidelines on tuberculosis in adults]. All-Russia Non-Commercial Organization of the Russian Society of Phthisiologists, National Association of Non-profit Organizations of Phthisiologists Association of Phthisiologists, 2022.
2. Klinicheskie rekomendatsii Tuberkulez u detey. [Clinical guidelines on tuberculosis in children]. All-Russia Non-Commercial Organization of the Russian Society of Phthisiologists, National Association of Non-profit Organizations of Phthisiologists Association of Phthisiologists, 2022.
3. Klinicheskie rekomendatsii. Latentnaya tuberkuleznaya infektsiya u detey. [Guidelines. Latent tuberculous infection in children]. All-Russia Non-Commercial Organization of the Russian Society of Phthisiologists, National Association of Non-profit Organizations of Phthisiologists Association of Phthisiologists, 2024.
4. Postnikov S.S., Semykin S.Yu., Nazhimov V.P., Kamenev A.I. Chondrotoxicity of fluoroquinolones in children: yes or no? Safety and Risk of Pharmacotherapy. 2015, no. 2, pp. 40-47. (In Russ.)
5. Edict no. 932n as of 15.11.12 by the Russian MoH On Approval of Procedure for Medical Care Provision to Tuberculosis Patients (with amendments and supplements). (In Russ.) Available: https://base.garant.ru/70340750/?ysclid=meogeztaw930488044 Accessed November 20, 2024
6. Adler-Shohet F.C., Low J., Carson M., Girma H., Singh J. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis. Pediatr. Infect. Dis. J., 2014, vol. 33, no. 6, pp. 664-666. https://doi.org/10.1097/INF.0000000000000260
7. Bamrah S., Brostrom R., Dorina F., Setik L., Song R., Kawamura L.M., Heetderks A., Mase S. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int. J. Tuberc. Lung Dis., 2014, vol. 18, no. 8, pp. 912-918. https://doi.org/10.5588/ijtld.13.0028
8. Dodd P.J., Sismanidis C., Seddon J.A. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis., 2016, vol. 16, no. 10, pp. 1193-1201. https://doi.org/10.1016/S1473-3099(16)30132-3
9. Garcia-Prats A.J., Zimri K., Mramba Z., Schaaf H.S., Hesseling A.C. Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation. Int. J. Tuberc. Lung Dis., 2014, vol. 18, no. 11, pp. 1292-1298. https://doi.org/10.5588/ijtld.13.0872.
10. Global consultation on best practices in the delivery of preventive therapy for household contacts of patients with drug-resistant tuberculosis. vol. 1, no. 1. Proceedings of the Harvard Medical School Center for Global Health Delivery, Dubai, 2015.
11. Global Tuberculosis Network, Migliori G.B., Tiberi S., Zumla A., Petersen E., Chakaya J.M., Wejse C., Muñoz Torrico M., Duarte R., Alffenaar J.W., Schaaf H.S., Marais B.J., Cirillo D.M., Alagna R., Rendon A., Pontali E., Piubello A., Figueroa J. et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 Clinical Update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 92, S15-S25. Advance online publication, 2020. https://doi.org/10.1016/j.ijid.2020.01.042
12. Global tuberculosis report, 2023. Geneva, World Health Organization, 2023. Licence: CC BY-NC-SA 3.0 IGO, 2023.
13. Gureva T., Turkova A., Yablokova E., Smirnova P., Sveshnikova O., Zolotaya O., Nikishova E., Heldal E., Hinderaker S., Seddon J.A., Mariandyshev A. Fluoroquinolone preventive therapy for children exposed to MDR-TB. Int. J. Tuberc. Lung Dis., 2022, vol. 26, no. 2, pp. 171-173. https://doi.org/10.5588/ijtld.21.0443
14. How to care for people exposed to drug-resistant tuberculosis: a practical guide. Boston, USA. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. First edition, 2018.
15. Jenkins H.E., Tolman A.W., Yuen C.M., Parr J.B., Keshavjee S., Pérez-Vélez C.M., Pagano M., Becerra M.C., Cohen T. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, 2014, vol. 383, no. 9928, pp. 1572-1579. https://doi.org/10.1016/S0140-6736(14)60195-1
16. Jenkins H.E., Yuen C.M. The burden of multidrug-resistant tuberculosis in children. Int. J. Tuberc. Lung Dis., 2018, vol. 22, no. 5, pp. 3-6. https://doi.org/10.5588/ijtld.17.0357
17. Malik A.A., Becerra M.C., Lash T.L., Cranmer L.M., Omer S.B.., Fuad J., Siddiqui S., Amanullah F. et al. Risk factors for adverse events in household contacts prescribed preventive treatment for drug-resistant tuberculosis exposure. Clin. Infect. Dis., 2021, vol. 72, no. 10, pp. 1709-1715. https://doi.org/10.1093/cid/ciaa327
18. Malik A.A., Fuad J., Siddiqui S., Amanullah F., Jaswal M., Barry Z., Jabeen F., Fatima R., Yuen C.M. et al. Tuberculosis preventive therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen. Clin. Infect. Dis., 2020, vol. 70, no. 9, pp. 1958-1965. https://doi.org/10.1093/cid/ciz502
19. Nahid P., Mase S.R., Migliori G.B., Sotgiu G., Bothamley G.H., Brozek J.L., Cattamanchi A., Cegielski J.P. et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am. J. Respir. Crit. Care Med., 2019, vol. 200, no. 10, pp. e93-e142. https://doi.org/10.1164/rccm.201909-1874ST
20. Patel K., Goldman J.L. Safety concerns surrounding quinolone use in children. British Journal of Clinical Pharmacology, 2016, vol. 56, no. 9, pp. 1060-1075. https://doi.org/10.1002/jcph.715
21. Radtke K.K., Hesseling A.C., Winckler J.L., Draper H.R., Solans B.P., Thee S., Wiesner L., van der Laan L.E. et al. Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. Clin. Infect. Dis., 2022, vol. 74, no. 8, pp. 1372-1381. https://doi.org/10.1093/cid/ciab641
22. Seddon J.A., Hesseling A.C., Finlayson H., Fielding K., Cox H., Hughes J., Godfrey-Faussett P., Schaaf H.S. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin. Infect. Dis., 2013, vol. 57, no. 12, pp. 1676-1684. https://doi.org/10.1093/cid/cit655
23. Shah N.S., Yuen C.M., Heo M., Tolman A.W., Becerra M.C. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis., 2014, vol. 58, no. 3, pp. 381-391. https://doi.org/10.1093/cid/cit643
24. Takizawa T., Hashimoto K., Minami T., Yamashita S., Owen, K. (1999). The comparative arthropathy of fluoroquinolones in dogs. Human and Experimental Toxicology, 1999, vol. 18, no. 6, pp. 392-399. https://doi.org/10.1191/096032799678840237
25. Trieu L., Proops D.C., Ahuja S.D. Moxifloxacin prophylaxis against MDR TB, New York, New York, USA. Emerg. Infect. Dis., 2015, vol. 21, no. 3, pp. 500-503. https://doi.org/10.3201/eid2103.141313
26. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 as of July 2017. Available: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf Accessed September 27, 2024
27. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva, World Health Organization, Licence. CC BY-NC-SA 3.0 IGO, 2020.
28. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. Geneva, World Health Organization. Licence: CC BY-NC-SA 3 IGO. WHO, 2024.
29. WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva, World Health Organization. Licence: CC BY-NC-SA 3.0 IGO, 2022.
Review
For citations:
Guryeva T.I., Nikishova E.I., Zolotaya O.A., Sveshnikova O.M., Perkhin D.V., Maryandyshev A.O. Preventive Treatment of Tuberculosis with Fluoroquinolones Including Moxifloxacin in Children Exposed to Multidrug-Resistant Tuberculosis. Tuberculosis and Lung Diseases. 2025;103(4):24-31. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-4-24-31
Views:
10
Email this article 